TECFIDERA is covered as a first-line relapsing MS (RMS) therapy (unrestricted access) for 87% of commercial patients as of March 2019—more first-line commercial coverage than any other oral RMS therapy.
*Coverage may vary, and there is no guarantee of coverage.
The $0 Copay Program provides a monthly supply of TECFIDERA. Eligible patients can enroll for as long as they are treated with TECFIDERA.
Federal and state laws may prevent eligibility. People covered by Medicare, Medicaid, the VA/DoD, or any other federal plans are not eligible to enroll. In addition, some insurance providers may prevent eligibility or restrict eligibility to people with demonstrated financial need. If patients are not eligible or not sure of their eligibility, they can call Above MS™. There are charitable programs and even a free drug program sponsored by Biogen that may be able to help with the cost.
Depending on patients’ income or, in some cases, if their medication is obtained from an out-of-network provider, there may be an annual cap that limits the amount of assistance they can receive over one year.
Reference: 1. Biogen, Data on file.